Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy

MeSH terms

• Antibodies, Monoclonal, Humanized / adverse effects*
• Carcinoma, Non-Small-Cell Lung / drug therapy*
• Carcinoma, Non-Small-Cell Lung / immunology
• Carcinoma, Non-Small-Cell Lung / metabolism
• Humans
• Immune Checkpoint Inhibitors / adverse effects*
• Integrin alpha4 / antagonists & inhibitors*
• Integrin alpha4 / immunology
• Integrin alpha4 / metabolism
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / immunology
• Lung Neoplasms / metabolism
• Male
• Meningoencephalitis / chemically induced
• Meningoencephalitis / drug therapy*
• Meningoencephalitis / immunology
• Meningoencephalitis / metabolism
• Middle Aged
• Natalizumab / therapeutic use*
• Programmed Cell Death 1 Receptor / antagonists & inhibitors*
• Programmed Cell Death 1 Receptor / immunology
• Programmed Cell Death 1 Receptor / metabolism
• Treatment Outcome